143 related articles for article (PubMed ID: 10197298)
1. Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis.
Cho HK; Lush RM; Bartlett DL; Alexander HR; Wu PC; Libutti SK; Lee KB; Venzon DJ; Bauer KS; Reed E; Figg WD
J Clin Pharmacol; 1999 Apr; 39(4):394-401. PubMed ID: 10197298
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis.
Bartlett DL; Buell JF; Libutti SK; Reed E; Lee KB; Figg WD; Venzon DJ; Alexander HR
Cancer; 1998 Sep; 83(6):1251-61. PubMed ID: 9740093
[TBL] [Abstract][Full Text] [Related]
3. Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma.
Ma GY; Bartlett DL; Reed E; Figg WD; Lush RM; Lee KB; Libutti SK; Alexander HR
Cancer J Sci Am; 1997; 3(3):174-9. PubMed ID: 9161783
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of cisplatin in semi-closed hyperthermic peritoneal perfusion (HPP) for treatment of peritoneal carcinomatosis.
Cattel L; De Simone M; Passera R; Verlengo MC; Delprino L
Anticancer Res; 2004; 24(3b):2041-5. PubMed ID: 15274398
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive surgery and continuous hyperthermic peritoneal perfusion in patients with mesothelioma and peritoneal carcinomatosis: hemodynamic, metabolic, and anesthetic considerations.
Miao N; Pingpank JF; Alexander HR; Royal R; Steinberg SM; Quezado MM; Beresnev T; Quezado ZM
Ann Surg Oncol; 2009 Feb; 16(2):334-44. PubMed ID: 19050961
[TBL] [Abstract][Full Text] [Related]
6. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer.
Steller MA; Egorin MJ; Trimble EL; Bartlett DL; Zuhowski EG; Alexander HR; Dedrick RL
Cancer Chemother Pharmacol; 1999; 43(2):106-14. PubMed ID: 9923815
[TBL] [Abstract][Full Text] [Related]
7. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP).
Park BJ; Alexander HR; Libutti SK; Wu P; Royalty D; Kranda KC; Bartlett DL
Ann Surg Oncol; 1999 Sep; 6(6):582-90. PubMed ID: 10493628
[TBL] [Abstract][Full Text] [Related]
8. [Continuous hyperthermic peritoneal perfusion with cisplatin and mitomycin C for peritoneal dissemination in gastric cancer].
Fujimura T; Yonemura Y; Urade M; Sugiyama K; Hasegawa H; Hashimoto T; Miyata R; Matsuda Y; Katayama K; Yamaguchi A
Nihon Gan Chiryo Gakkai Shi; 1989 Jul; 24(7):1415-24. PubMed ID: 2509604
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of cisplatin after intraoperative hyperthermic intraperitoneal chemoperfusion (HIPEC).
Zeamari S; Floot B; van der Vange N; Stewart FA
Anticancer Res; 2003; 23(2B):1643-8. PubMed ID: 12820435
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic outcomes of continuous hyperthermic peritoneal perfusion against advanced gastric cancer with peritoneal carcinomatosis.
Kunisaki C; Shimada H; Akiyama H; Nomura M; Matsuda G; Otsuka Y; Ono H; Takahashi M
Hepatogastroenterology; 2006; 53(69):473-8. PubMed ID: 16795995
[TBL] [Abstract][Full Text] [Related]
11. Local and systemic exposure of cisplatin during hyperthermic intrathoracic chemotherapy perfusion after pleurectomy and decortication for treatment of pleural malignancies.
Ried M; Potzger T; Braune N; Diez C; Neu R; Sziklavari Z; Schalke B; Hofmann HS
J Surg Oncol; 2013 Jun; 107(7):735-40. PubMed ID: 23386426
[TBL] [Abstract][Full Text] [Related]
12. Treatment of peritoneal carcinomatosis by continuous hyperthermic peritoneal perfusion with cisplatin.
Alexander HR; Fraker DL
Cancer Treat Res; 1996; 81():41-50. PubMed ID: 8834574
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis.
Cashin PH; Ehrsson H; Wallin I; Nygren P; Mahteme H
Eur J Clin Pharmacol; 2013 Mar; 69(3):533-40. PubMed ID: 22983312
[TBL] [Abstract][Full Text] [Related]
14. Continuous hyperthermic peritoneal perfusion for peritoneal carcinomatosis.
Chung YC; Huang MT; Chang CN; Huang TW
J Formos Med Assoc; 1996 Feb; 95(2):138-43. PubMed ID: 9064002
[TBL] [Abstract][Full Text] [Related]
15. Does hyperthermia induce peritoneal damage in continuous hyperthermic peritoneal perfusion?
Shido A; Ohmura S; Yamamoto K; Kobayashi T; Fujimura T; Yonemura Y
World J Surg; 2000 May; 24(5):507-11. PubMed ID: 10787067
[TBL] [Abstract][Full Text] [Related]
16. Continuous hyperthermic peritoneal perfusion with cisplatin in mice with peritoneal dissemination of B16 melanoma.
Okuyama T; Endo K; Maehara Y; Baba H; Oshiro T; Adachi Y; Sugimachi K
Semin Surg Oncol; 1994; 10(2):145-9. PubMed ID: 8052785
[TBL] [Abstract][Full Text] [Related]
17. Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity.
Kern W; Braess J; Kotschofsky M; Samel S; Becker H; Hiddemann W; Schleyer E
Anticancer Res; 2002; 22(5):3099-102. PubMed ID: 12530050
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy.
Panteix G; Beaujard A; Garbit F; Chaduiron-Faye C; Guillaumont M; Gilly F; Baltassat P; Bressolle F
Anticancer Res; 2002; 22(2B):1329-36. PubMed ID: 12168946
[TBL] [Abstract][Full Text] [Related]
19. Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study.
Rossi CR; Foletto M; Mocellin S; Pilati P; De SM; Deraco M; Cavaliere F; Palatini P; Guasti F; Scalerta R; Lise M
Cancer; 2002 Jan; 94(2):492-9. PubMed ID: 11900234
[TBL] [Abstract][Full Text] [Related]
20. [Continuous hyperthermic peritoneal perfusion (CHPP) for prevention or treatment of peritoneal dissemination].
Kusano H; Miyashita K; Matsuo T; Jibiki M; Nakagoe T; Miura T; Tomita M
Gan To Kagaku Ryoho; 1993 Aug; 20(11):1622-5. PubMed ID: 8373233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
